RxDoctor Payments Data

Saul Burciaga-Molinar, MD

Family Medicine · Las Cruces, NMNPI 1790960383

Payments from drug & device makers

$1,258in general payments, 2019–2025

Across 72 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$398
  • Sanofi-aventis U.S. LLC$179
  • Novo Nordisk$157
  • GSK$143
  • AbbVie$107
  • BD$87
  • plus $186 from 6 others

What the payments were for

  • Food & beverage$1,24299%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,258 in reported general payments places this provider in the 80th percentile of 717 family medicine providers in New Mexico.

See all family medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$71,589
Medicare patients
169
Services billed
684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide148$180,589
JardianceEmpagliflozin169$155,245
RybelsusSemaglutide54$88,179
FarxigaDapagliflozin Propanediol69$61,446
TrulicityDulaglutide51$58,854
MounjaroTirzepatide37$39,714
EliquisApixaban21$21,593
JanuviaSitagliptin Phosphate13$20,485
Tresiba Flextouch U-100Insulin Degludec31$20,049
TradjentaLinagliptin12$13,500
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,833
MultaqDronedarone Hcl12$10,695
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$7,408
Gabapentin264$4,976
SymbicortBudesonide/Formoterol Fumarate12$4,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$157$268,768202 claims
Lilly USA, LLCTrulicity, Mounjaro$398$98,56888 claims
AstraZenecaFarxiga, Symbicort$70$65,65881 claims
MerckJanuvia$21$20,48513 claims
GSKTrelegy Ellipta$143$10,83312 claims
Sanofi-aventis U.S. LLCMultaq$179$10,69512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 717 family medicine providers in New Mexico.

Other family medicine in Las Cruces

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →